Haemonetics Corporation (HAE)

Working capital turnover

		Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	US$ in thousands	1,360,820	1,309,060	1,168,660	993,196	870,463
Total current assets	US$ in thousands	934,975	768,903	769,722	756,031	693,546
Total current liabilities	US$ in thousands	578,113	300,383	251,816	442,266	253,495
Working capital turnover		3.81	2.79	2.26	3.17	1.98

March 31, 2025 calculation

Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $1,360,820K ÷ ($934,975K – $578,113K)
= 3.81

Haemonetics Corporation's working capital turnover has shown fluctuations over the years based on the provided data.

- In March 31, 2021, the working capital turnover was 1.98, indicating that the company generated $1.98 in revenue for every $1 of working capital invested.
- The ratio improved significantly to 3.17 by March 31, 2022, suggesting that the company became more efficient in utilizing its working capital to generate revenue.
- However, there was a slight decline in efficiency as the ratio dropped to 2.26 on March 31, 2023, indicating a potential dip in revenue generation relative to working capital.
- In March 31, 2024, the ratio improved to 2.79, showing a recovery in utilizing working capital effectively to generate revenue.
- Unfortunately, the data for March 31, 2025 is unavailable, making it challenging to assess the company's recent performance in terms of working capital turnover.

Overall, fluctuations in the working capital turnover ratio indicate varying levels of efficiency in utilizing working capital to generate revenue. It is essential for Haemonetics Corporation to maintain a balance to ensure optimal utilization of working capital for revenue generation.